TScan Therapeutics, Inc.

TScan Therapeutics, Inc. (TCRX) priced its initial public offering on Jul 19, 2021 at $15.00 per share, within its $15.00–$17.00 range, raising $100M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $359.1M. Gunderson Dettmer advised the company and Davis Polk advised the underwriters.

TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its TargetScan platform analyzes T cells of patients with exceptional immunotherapy responses to identify targets recognized by their T cell receptors.

Status

IPO

Ticker

TCRX

Exchange

Nasdaq Global Market

Priced

Jul 19, 2021

IPO price

$15.00

Price range

$15.00–$17.00

Raised

$100M

Market cap at IPO price

$359.1M

First filed

Apr 23, 2021

Company counsel

Gunderson Dettmer

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.